HCPLive Podcasts

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! FDA Accepts Priority Review Application of Omidubicel for Severe Aplastic Anemia  The FDA accepted a priority review application for omidubicel, a cell therapy under investigation for severe aplastic anemia. FDA Approves REMS Label Update for Sparsentan (Filspari) in IgA Nephropathy  The FDA approved an updated REMS label for sparsentan, easing monitoring requirements for patients with IgA nephropathy. FDA Issues CRL to Outlook Therapeutics' ONS-5010 for the Treatment of Wet AMD The FDA issued a complete response letter for ONS-5010 in wet AMD, citing insufficient efficacy evidence from the phase 3 program. ACC Releases Respiratory Disease Vaccination Guidelines for Adults with Heart Disease The ACC released new guidance recommending vaccination against respiratory infections for adults with cardiovascular disease to improve prevention and access. Orforglipron Delivers Weight Loss, A1C Reductions in Phase 3 ATTAIN-2 Trial Eli Lilly reported phase 3 results showing orforglipron improved weight and glycemic control in adults with obesity or overweight and type 2 diabetes.

In this podcast, expert Suneel Udani, MD, discusses the management of chronic kidney disease (CKD) and CKD-associated fluid overload, including an overview of treatment guidelines and various available therapies.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for August 17-23, 2025: 1. FDA Approves Donidalorsen to Prevent Hereditary Angioedema Attacks The FDA approved donidalorsen (DAWNZERA) for preventing HAE attacks in patients 12 years and older, supported by phase 3 OASIS trial data. 2. FDA Grants Atumelnant Orphan Drug Designation for Congenital Adrenal Hyperplasia Atumelnant received FDA Orphan Drug Designation after phase 2 results showed rapid, sustained reductions in key biomarkers for congenital adrenal hyperplasia. 3. Semaglutide Reduces Medical Costs, Healthcare Resource Utilization in Heart Failure A real-world analysis found semaglutide 2.4 mg reduced all-cause medical costs by 28% and inpatient hospitalization costs by 55% in patients with obesity and heart failure. 4. RE104 Reduces Postpartum Depression Symptoms by Day 7 in Phase 2 RECONNECT RE104 significantly reduced depressive symptoms by day 7 in patients with postpartum depression, meeting the phase 2 RECONNECT trial’s primary endpoint. 5. Dyslipidemia, Other Metabolic Syndrome Factors May Raise Parkinson’s Disease Risk People with metabolic syndrome had about a 40% higher risk of developing Parkinson’s disease compared with those without the condition.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for August 10-16, 2025: FDA Approves 2 Generic Iron Sucrose Injections for Iron Deficiency Anemia in CKD  The FDA approved 2 generic versions of iron sucrose injection for treating iron deficiency anemia in patients with CKD, expanding access to therapy. FDA Approves PharmaTher’s Ketamine for Surgical Pain Management  The FDA approved PharmaTher’s ketamine formulation for surgical pain management following resolution of earlier application deficiencies. HFSA and ASPC Release Statement on Shifting to Prevention in Heart Failure  The HFSA and ASPC issued a joint statement urging clinicians to prioritize prevention and early risk management in heart failure care. Zopapogene Imadenovec First Immunotherapy Approved for Recurrent Respiratory Papillomatosis  The FDA approved zopapogene imadenovec as the first immunotherapy for recurrent respiratory papillomatosis, offering a new treatment option. AHA & ACC Release New Guidelines for High Blood Pressure to Reduce CVD Risk  The AHA and ACC released updated hypertension guidelines recommending earlier intervention to lower cardiovascular disease risk.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for August 3-9, 2025: FDA Approves Fremanezumab to Prevent Episodic Migraine in Children The FDA has expanded fremanezumab’s indication to include pediatric patients 6–17 years old, making it the first CGRP antagonist approved for preventing episodic migraine in this population. ATTAIN-1: Orforglipron Achieves Up to 12% Weight Loss in Phase 3 Obesity Trial  Orforglipron, an investigational oral GLP-1 receptor agonist, met all primary and secondary endpoints in phase 3, supporting its potential as a weight-management therapy. Oral Berotralstat Shows Strong Safety, Efficacy in Young Children with HAE Interim phase 3 data support oral berotralstat as a safe and effective prophylactic therapy for hereditary angioedema in children aged 2–11 years. Aflibercept 8mg Noninferior to Aflibercept 2mg in Diabetic Macular Edema  Aflibercept 8 mg demonstrated noninferior visual acuity outcomes to 2 mg dosing in DME, with potential for reduced injection frequency. Despite Advances, IBS Continues to Impact Patients' Daily Lives, Productivity  A new national survey reveals ongoing quality-of-life and productivity burdens among IBS patients despite greater awareness and expanded treatment options.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for July 7-13, 2025: FDA Approves Finerenone (Kerendia) for Heart Failure with Ejection Fraction of 40% or More Finerenone (Kerendia) was approved on July 14, 2025, to reduce cardiovascular death and heart failure hospitalizations in adults with HFmrEF or HFpEF, based on data from the FINEARTS-HF trial. Baxdrostat Meets Efficacy Endpoint in Phase 3 Trial for Resistant Hypertension In the phase 3 BaxHTN trial, baxdrostat significantly reduced systolic blood pressure in patients with resistant hypertension, supporting its potential as a first-in-class aldosterone synthase inhibitor. FDA Approves Updated VARIPULSE Platform Irrigation Flow Rate for Heart Disease The FDA approved an updated irrigation flow rate for the VARIPULSE Platform, which has been used in over 10,000 procedures with a reported neurovascular adverse event rate of less than 0.5%. Palopegteriparatide Provides Sustained Response in Adults with Hypoparathyroidism Palopegteriparatide showed durable 3-year improvements in biochemistries, kidney function, and quality of life across all forms of hypoparathyroidism in the phase 3 PaTHway trial. FDA Grants Orphan Drug Designation to Taladegib, Potential Idiopathic Pulmonary Fibrosis Treatment Taladegib received Orphan Drug Designation on July 16, 2025, as a potential treatment for idiopathic pulmonary fibrosis, currently being studied in the phase 2b WHISTLE-PF trial.

In this episode, hosts Kimberly Brown, MD, and Nancy Reau, MD, discuss the progress and persistent challenges in eliminating hepatitis C (HCV). With highly effective, short-course oral therapies now available, Brown and Reau emphasize that curing HCV is more achievable than ever. The discussion explores the major policy, clinical, and structural milestones enabling this effort—and the critical gaps in diagnosis, treatment access, and health policy that still impede progress.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for June 30-July 6, 2025: Sebetralstat FDA-Approved as First Oral, On-Demand for Hereditary Angioedema The FDA approved sebetralstat (Ekterly) on July 7, 2025, as the first oral, on-demand treatment for hereditary angioedema attacks in patients aged 12 and older, backed by phase 3 KONFIDENT trial data. Rilparencel Improves eGFR Slope in Phase 2 CKD, Diabetes REGEN-007 Trial Rilparencel significantly slowed kidney function decline in CKD patients with diabetes in the REGEN-007 trial, showing dose-responsive eGFR slope improvements after two injections per kidney. J&J Submits sNDA to FDA for Lumateperone (CAPLYTA) to Prevent Schizophrenia Relapse J&J filed a supplemental NDA for lumateperone after phase 3 data showed a 63% reduction in schizophrenia relapse risk compared to placebo. FDA Publishes CRLs for Past Drug, Biological Product Applications The FDA publicly released over 200 Complete Response Letters from 2020–2024 to increase regulatory transparency and help accelerate future drug approvals. FDA Grants TSND-201 Breakthrough Therapy Designation for PTSD TSND-201 (methylone) received Breakthrough Therapy designation for PTSD on July 10, 2025, offering a potential rapid-acting alternative to SSRIs, which can take up to 12 weeks for full effect.

In this episode of New Insight, host Veeral Sheth, MD, MBA, director of clinical research at University Retina and Macula Associates, speaks with Roland Mattern, director of marketing for eSight, about the development and clinical potential of the eSight Go – a fifth-generation wearable low-vision device designed to enhance central visual function in patients with conditions such as macular degeneration, diabetic retinopathy, and Stargardt’s disease. 00:00 - Intro 02:06 - History of eSight 05:43 - Difference Between 4th and 5th Generation eSight Go 07:51 - Patient Experiences with the eSight Go 10:22 - Returning to Daily Life with the eSight Go 13:27 - Why Retina Specialists Don't Hear About the eSight Go 17:07 - Next Steps for eSight

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for June 16-22, 2025: Pemvidutide Shows Significant MASH Effects, Weight Loss at 24 Weeks in Phase 2b IMPACT Trial Topline phase 2b data show pemvidutide achieved significant rates of MASH resolution and fibrosis improvement alongside meaningful weight loss at 24 weeks, positioning it as a promising candidate for metabolic liver disease treatment. FDA Approves Belimumab (Benlysta) Autoinjector for Pediatric Lupus Nephritis The FDA approved a belimumab autoinjector for at-home subcutaneous use in children as young as five with active lupus nephritis, providing the first approved biologic self-injection option for pediatric SLE and LN. Phase 3 Trial Results Announced for Sotatercept-csrk in Pulmonary Arterial Hypertension Positive phase 3 results show sotatercept-csrk added to background therapy reduced time to clinical worsening events in adults with PAH, supporting its potential as an effective treatment for this high-risk population. Compass Pathways’ COMP360 Psilocybin Shows Benefit in Phase 3 TRD Trial COMP360 psilocybin demonstrated a significant reduction in depression symptom severity in treatment-resistant depression, meeting the primary endpoint in a pivotal phase 3 trial. Once-Monthly Obesity Drug, MariTide, Achieves Weight Loss Up to 16% at 1 Year Phase 2 data indicate once-monthly MariTide induces substantial weight loss of up to 16% over one year, with additional improvements in glycemic control, highlighting its promise for obesity and type 2 diabetes management.

In this episode of Medical Ethics Unpacked, hosts Dominic Sisti and Steve Levine welcome Jason Schwartz, PhD, associate professor at the Yale School of Public Health, for a discussion on vaccine ethics, public health infrastructure, and the challenges of maintaining trust in immunization programs. Together, they explore how the COVID-19 pandemic reshaped public attitudes toward vaccines, while also underscoring long-standing tensions between individual autonomy and collective responsibility. Schwartz, whose work focuses on vaccine policy and history, offers perspective on the systems and institutions, such as the CDC's Advisory Committee on Immunization Practices (ACIP), helping to translate scientific evidence into public health recommendations. This episode comes at a time when ACIP is once again in the headlines as HHS Secretary Robert F. Kennedy Jr. recently replaced all 17 members with a new slate of individuals, citing concerns about groupthink and conflicts of interest. The move has generated widespread commentary about the role and value of such expert advisory bodies in shaping public health decisions, especially in the face of growing skepticism and political scrutiny. Ethical questions about equity, communication, and responsibility are threaded throughout the discussion. The hosts and Schwartz reflect on what it means to make fair vaccine recommendations in the context of incomplete data, and how institutions can maintain public trust amid scientific uncertainty. They also discuss how the infrastructure behind public health decisions—committees, advisory boards, and interagency coordination—can either strengthen or undermine confidence depending on how they function and how well they are understood. Chapters 00:00 – Introduction and Vaccine Policy in Crisis 03:00 – The Long History and New Politics of Vaccine Skepticism 09:30 – Erosion of Public Health Infrastructure and Expert Advisory Systems 14:50 – Why Vaccines Became a Political Flashpoint 19:10 – Clinician Ethics and the Vaccine-Hesitant Patient 32:00 – Data, Misinformation, and the Future of Vaccine Trust References: Stone W. RFK Jr. names new slate of vaccine advisers after purging CDC panel. NPR. Published June 11, 2025. Accessed June 17, 2025. https://www.npr.org/sections/shots-health-news/2025/06/11/nx-s1-5430870/cdc-vaccine-experts-rfk-jr Asturias EJ, Brewer NT, Brooks O, et al. Advisory Committee on Immunization Practices at a Crossroads. JAMA. Published online June 16, 2025. doi:10.1001/jama.2025.10776

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for June 2-8, 2025. FDA Approves Clesrovimab RSV Immunization for Newborns and Infants The FDA has approved clesrovimab (Enflonsia) for the prevention of RSV lower respiratory tract disease in infants, based on results from two late-stage clinical trials evaluating its safety and efficacy. FDA Approves Glecaprevir/Pibrentasvir (Mavyret) Label Expansion for Acute HCV The FDA has expanded the indication for glecaprevir/pibrentasvir to include treatment of acute hepatitis C virus infection in adults and children aged three years and older, regardless of cirrhosis status. FDA Approves Prednisolone Acetate Ophthalmic Suspension for Ocular Inflammation Prednisolone acetate ophthalmic suspension 1% has received FDA approval as a topical steroid treatment for steroid-responsive ocular inflammation, with product launch expected later in 2025. FDA Grants Fast Track Designation to Mavorixafor for Chronic Neutropenia The FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia, supporting its ongoing phase 3 evaluation following earlier approval for WHIM syndrome. Iptacopan (Fabhalta) Hits Primary Endpoint in Phase 3 APPULSE-PNH Trial Phase 3 data show iptacopan (Fabhalta) is effective and well-tolerated in adults with PNH who transitioned from anti-C5 therapy, achieving key hematologic outcomes and symptomatic improvement.

In this episode of Liver Lineup: Updates & Unfiltered Insights, hosts Kimberly Brown, MD, a professor of Medicine at Michigan State University and Wayne State University, associate medical director of the Henry Ford Hospital Transplant Institute, and medical director of Transplant Outreach Services at Henry Ford Hospital, and Nancy Reau, MD, a professor of internal medicine, the Richard B. Capps Chair of Hepatology, associate director of solid organ transplantation, and the section chief of hepatology at Rush University Medical Center, continue their discussion on notable abstracts presented at the 2025 European Association for the Study of the Liver (EASL) Congress. If you haven't already, be sure to check out part 1 here! Key Episode Timestamps 0:00:00 LITMUS Study 0:05:47 Norursodeoxycholic Acid in PSC 0:10:12 GLOBE Score for PBC 0:15:11 Conclusion Arbutus, and VIR. Relevant disclosures for Brown include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal.

In this episode of Liver Lineup: Updates & Unfiltered Insights, hosts Kimberly Brown, MD, a professor of Medicine at Michigan State University and Wayne State University, associate medical director of the Henry Ford Hospital Transplant Institute, and medical director of Transplant Outreach Services at Henry Ford Hospital, and Nancy Reau, MD, a professor of internal medicine, the Richard B. Capps Chair of Hepatology, associate director of solid organ transplantation, and the section chief of hepatology at Rush University Medical Center, highlight 4 key abstracts presented at the 2025 European Association for the Study of the Liver (EASL) Congress. Key Episode Timestamps 00:00:01 Introduction 00:00:45 Efimosfermin Alfa in MASH 00:05:56 PEth Testing 00:13:19 RETRACT-B 00:20:44 Linerixibat in PBC Relevant Disclosures for Reau include AbbVie, Gilead, Salix, Arbutus, and VIR. Relevant disclosures for Brown include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for May 12-18, 2025. FDA Approves Once-Daily Roflumilast (ZORYVE) Foam 0.3% for Scalp and Body Psoriasis The FDA approved once-daily roflumilast (Zoryve) foam 0.3% for treating plaque psoriasis on the scalp and body in patients aged 12 and older. This marks the fifth overall indication for roflumilast, adding to its existing approvals in psoriasis and atopic dermatitis. FDA Warns About Rare, Severe Itching After Stopping Cetirizine or Levocetirizine The FDA issued a warning about severe pruritus that can occur after stopping long-term cetirizine or levocetirizine use. Manufacturers will be required to add a label warning noting that symptoms may improve if the medications are restarted. FDA Approves Susvimo for Treatment of Diabetic Retinopathy The FDA approved Genentech’s Susvimo, a ranibizumab delivery system, as the first continuous refillable treatment for diabetic retinopathy. Susvimo offers sustained vision maintenance with refills needed only once every nine months. Olezarsen Cuts Triglyceride Levels at 6 Months in Essence Study The Essence study showed olezarsen significantly reduced triglyceride levels in patients with moderate hypertriglyceridemia at ASCVD risk. Monthly doses achieved about 60% reductions, with most patients reaching normal triglyceride levels after six months. Ruxoprubart Shows Efficacy for PNH in Interim Phase 2 Trial Results Interim Phase 2 results showed ruxoprubart met all primary efficacy endpoints in adults with paroxysmal nocturnal hemoglobinuria. The therapy led to transfusion avoidance, improved hemoglobin, reduced LDH, and increased PNH clone size at 12 weeks.